Platinum-sensitive recurrent is defined as the first recurrence after completion of primary treatment of at least 6 months without any evidence of disease.
Secondary analyses were the time to the first recurrence in the entire population and the time to the first recurrence in those with significant structural heart disease.
Patients died most frequently (63.2%) up to 30 months after the first recurrence.
Here only the proof of the first recurrence will be provided.
We identified three prognostic factors: age at breast cancer diagnosis, the histological grade and the site of the first recurrence.
A pattern of lung metastasis as the first recurrence may be a favorable prognostic factor in patients with relapsed PDAC; however, the mechanism remained unclear.
Based on multivariate analysis, the four factors that were most predictive of survival after the first recurrence were disease-free interval, site of recurrence, progesterone receptor (PgR) status, and vascular involvement.
These findings showed that the intrinsic tumor biology of the initial primary tumor plays a critical role in determining survival after the first recurrence in patients with a breast carcinoma.
We present a patient who developed a solitary BCLM as the first recurrence and yet achieved long-term disease-free survival after aggressive human epidermal growth factor receptor 2 (HER2 -directed cHER2 -directedd hepatichemotherapytomy.
Time to RFS is defined as the time between surgery and the first recurrence of local, regional or distant-metastatic breast tumor or the last date of follow-up.
Table 2 shows the first recurrence site.
